TY - JOUR
T1 - MiR-187 targets the androgen-regulated gene ALDH1A3 in prostate cancer
AU - Casanova-Salas, Irene
AU - Masiá, Esther
AU - Armiñán, Ana
AU - Calatrava, Ana
AU - Mancarella, Caterina
AU - Rubio-Briones, José
AU - Scotlandi, Katia
AU - Vicent, Maria Jesús
AU - López-Guerrero, José Antonio
PY - 2015/5/13
Y1 - 2015/5/13
N2 - miRNAs are predicted to control the activity of approximately 60% of all protein-coding genes participating in the regulation of several cellular processes and diseases, including cancer. Recently, we have demonstrated that miR-187 is significantly downregulated in prostate cancer (PCa) and here we propose a proteomic approach to identify its potential targets. For this purpose, PC-3 cells were transiently transfected with miR-187 precursor and miRNA mimic negative control. Proteins were analyzed by a two-dimensional difference gel electrophoresis (2D-DIGE) and defined as differentially regulated if the observed fold change was ±1.06. Then, MALDI-TOF MS analysis was performed after protein digestion and low abundance proteins were identified by LC-MS/MS. Peptides were identified by searching against the Expasy SWISS PROT database, and target validation was performed both in vitro by western blot and qRT-PCR and in clinical samples by qRT-PCR, immunohistochemistry and ELISA. DIGE analysis showed 9 differentially expressed spots (p
AB - miRNAs are predicted to control the activity of approximately 60% of all protein-coding genes participating in the regulation of several cellular processes and diseases, including cancer. Recently, we have demonstrated that miR-187 is significantly downregulated in prostate cancer (PCa) and here we propose a proteomic approach to identify its potential targets. For this purpose, PC-3 cells were transiently transfected with miR-187 precursor and miRNA mimic negative control. Proteins were analyzed by a two-dimensional difference gel electrophoresis (2D-DIGE) and defined as differentially regulated if the observed fold change was ±1.06. Then, MALDI-TOF MS analysis was performed after protein digestion and low abundance proteins were identified by LC-MS/MS. Peptides were identified by searching against the Expasy SWISS PROT database, and target validation was performed both in vitro by western blot and qRT-PCR and in clinical samples by qRT-PCR, immunohistochemistry and ELISA. DIGE analysis showed 9 differentially expressed spots (p
UR - http://www.scopus.com/inward/record.url?scp=84929379752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929379752&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0125576
DO - 10.1371/journal.pone.0125576
M3 - Article
AN - SCOPUS:84929379752
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 5
M1 - e0125576
ER -